Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC
Hou‐Qun Ying, Yu‐Cui Liao, Yan-Ran Luo, Gang Xiong, Ying Huang, Ruo-Wei Nie, Cui-Fen Xiong, Xue‐Xin Cheng
Topics & Concepts
MedicineInternal medicineCohortOncologyBiomarkerProportional hazards modelCancerLung cancerLogistic regressionTyrosine-kinase inhibitorBiologyBiochemistryInflammatory Biomarkers in Disease PrognosisCancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations